Kura Starts Phase 1 Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma

  Company anticipates dosing of KO-2806 in combination with adagrasib in KRASG12C-mutant NSCLC next quarter –

– Dose escalation of KO-2806 as a monotherapy continues in parallel –

Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced dosing of the first patient with KO-2806, the Company’s next-generation farnesyl transferase inhibitor (FTI), in combination with the tyrosine kinase inhibitor (TKI) cabozantinib in the clear cell renal cell carcinoma (ccRCC) cohort of the Phase 1 portion of the FIT-001 trial.

https://www.globenewswire.com/news-release/2024/03/06/2841290/35186/en/Kura-Oncology-Reports-First-Patient-Dosed-in-Trial-of-KO-2806-Plus-Cabozantinib-in-Renal-Cell-Carcinoma.html